Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial

Thrombo-inflammation is central to COVID-19-associated coagulopathy. TF (tissue factor), a driver of disordered coagulation and inflammation in viral infections, may be a therapeutic target in COVID-19. The safety and efficacy of the novel TF inhibitor rNAPc2 (recombinant nematode anticoagulation pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hess, Connie N., Hsia, Judith, Carroll, Ian A., Nehler, Mark R., Ruf, Wolfram, Morrow, David A., Nicolau, Jose C., Berwanger, Otavio, Szarek, Michael, Capell, Warren H., Johri, Shilpa, Pursley, Michael S., Gupta, Ryan, Meehan, Patrick S., Franchi, Francesco, Effron, Mark B., Marshall, Debra, Graybill, Christopher A., Huebler, Sophia P., Keuer, Thomas, Bristow, Michael R., Bonaca, Marc P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Clinical and Population Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364965/
https://www.ncbi.nlm.nih.gov/pubmed/37381988
http://dx.doi.org/10.1161/ATVBAHA.122.318748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364965/
https://www.ncbi.nlm.nih.gov/pubmed/37381988
http://dx.doi.org/10.1161/ATVBAHA.122.318748

Ejemplares similares